Tianda Pharmaceuticals (HKSE:00455) Total Liabilities : HK$325.4 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Total Liabilities?

Tianda Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was HK$325.4 Mil.

Tianda Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2022 (HK$335.09 Mil) to Jun. 2023 (HK$340.94 Mil) but then declined from Jun. 2023 (HK$340.94 Mil) to Dec. 2023 (HK$325.35 Mil).

Tianda Pharmaceuticals's annual Total Liabilities increased from Mar. 2021 (HK$342.97 Mil) to Mar. 2022 (HK$375.08 Mil) but then declined from Mar. 2022 (HK$375.08 Mil) to Dec. 2023 (HK$325.35 Mil).

Tianda Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Tianda Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Total Liabilities Chart

Tianda Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Dec23

Total Liabilities

Get a 7-Day Free Trial

185.80

173.36

342.97

375.08

325.35

Tianda Pharmaceuticals Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															348.27	375.08	335.09	340.94	325.35

Tianda Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tianda Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	313.312	+	(11.427	+	0.61100000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	325.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	917.291	-	591.941
	=	325.4

Tianda Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	313.312	+	(11.427	+	0.61100000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	325.4

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	917.291	-	591.941
	=	325.4

Tianda Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianda Pharmaceuticals (HKSE:00455) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG

Website

https://www.tiandapharma.com

Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.

Executives

Tianda Group Limited	2101 Beneficial owner
Fang Wen Quan	2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines